Enterprises from 39 Countries Join WCIFIT, with Thailand, Hong Kong, and Sichuan in the Spotlight
The fair also featured the debut of Lingjie, the world's first megawatt-class supercharging heavy-duty truck, co-developed by Qingling Motors and Huawei Digital Power. With ultra-fast charging and smart connectivity, it marks a major step forward in green logistics and heavy-duty transport electrification.
Centered around the theme 'New Western China, New Manufacturing, New Services,' this year's fair highlights cultivating new quality productive forces and promoting high-quality development.
56 Chinese central state-owned enterprises, 156 local state-owned enterprises, 47 Fortune Global 500 companies, 93 multinational corporations, and 286 leading private enterprises participated.
Thailand is participating as the guest country of honor, Sichuan Province continues its role as the permanent guest province, and the Hong Kong Special Administrative Region joins as the new guest city of honor.
Dr. Lalivan Karnchanachari, Vice Minister to Ministry of Foreign Affairs of Thailand, highlighted the significance of this year marking the 50th anniversary of diplomatic ties between China and Thailand. She expressed hopes for deeper cooperation with Chongqing in high value-added manufacturing, supply chains, and SME development.
At the opening ceremony, a series of major investment deals were signed, with the total amount exceeding 200 billion yuan (about 27.6 billion USD). Districts and counties across Chongqing secured agreements worth over 100 billion yuan, with more than 75% of the investment directed toward the manufacturing and modern services sectors.
Showcasing both exhibitions and themed activities, this year's WCIFIT exhibition spans three major sections—comprehensive image, international and regional cooperation, and modern industry—covering nine halls across 110,000 square meters. A virtual exhibition hall has also been launched to extend access online.
Themed activities include 29 events focused on key areas such as the productive service industry, foreign investment, international trade, public sector engagement, and special programs hosted by the guest of honor.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
an hour ago
- The Star
Electric vehicle sales growth eases to 21% in July
China's overall car sales growth slowed in July, with BYD , the world's largest EV maker, recording its third monthly drop in registrations. — Bloomberg SHANGHAI: Global electric vehicle (EV) sales grew 21% year-on-year in July, the slowest rate since January and down from 25% in June, as momentum in plug-in hybrid sales in China slackened, market research firm Rho Motion says. China is the world's biggest car market and accounts for more than half of global EV sales, which in Rho Motion's data include battery-electric vehicles and plug-in hybrids. Its overall car sales growth slowed in July, with BYD , the world's largest EV maker, recording its third monthly drop in registrations. The relatively muted slowdown in overall EV sales, however, showed other markets are taking up some of the slack, with European sales for one benefitting from incentives aimed at speeding up decarbonisation. Global sales of battery-electric vehicles and plug-in hybrids rose to 1.6 million units in July, Rho Motion data showed. China's EV sales growth, which averaged 36% a month in the first half, eased to 12% in July as the previously booming market was dampened by a pause in some 2025 government subsidy schemes for EV and plug-in hybrid purchases, Rho Motion data manager Charles Lester said. Chinese sales reached around one million vehicles. European sales surged 48% to about 390,000 units, while North American sales climbed 10% to more than 170,000. Sales in the rest of the world jumped 55% to more than 140,000 vehicles. 'Despite regional variations, the overall trajectory for EV adoption in 2025 remains strongly upward,' Lester said. Chinese car sales are expected to return to strong growth from August as new funds become available for its subsidy schemes, while a cut in US tax credits for buying or leasing new EVs at the end of September will hurt demand there, Lester added. — Reuters
The Star
an hour ago
- The Star
White goods exports show uptick in 1H25
BEIJING: China's exports of home appliances grew steadily in the first half of the year, with emerging markets including Latin America, the Middle East and Asean showing an upward trajectory, according to a report by an industry association. Data from the China Chamber of Commerce for Import and Export of Machinery and Electronic Products show that the cumulative export value of Chinese white goods – which refer to large household appliances like refrigerators, washing machines and air conditioners – stood at US$68.78bil in the first six months, up 6.2% year-on-year (y-o-y). China's exports of household appliances to Asia rose 8.4% y-o-y to US$26.92bil during the period, while those to the European market increased 9.8% on a yearly basis, the report said. However, the country's household appliance exports to traditional markets such as North America, Australia and New Zealand declined during the January-June period, affected by rising trade protectionism and volatile tariff policies from the United States. Exports to the North American market reached US$11.87bil, down 5% compared with the same period last year due to US tariff hikes, the report noted. Moreover, with scorching temperatures gripping much of the Northern Hemisphere, the export volume of China-made air conditioners came up to nearly 57 million units in the first half. The figure is expected to exceed 90 million units by the end of this year. Exports of Chinese home appliance components maintained growth momentum in the first six months, with the export value reaching US$10.9bil, surging 18.6% from a year earlier, the report added. Zhou Nan, secretary-general of the CCCME's home appliances branch, said the demand for Chinese white goods in emerging markets such as South-East Asia, Africa and the Middle East is growing rapidly, providing new growth momentum for China's household appliance exports. 'Some Middle Eastern countries, such as the United Arab Emirates and Saudi Arabia, have accelerated economic transformation, expecting more Chinese companies to invest and start businesses there, which brings about new development opportunities for Chinese brands,' he said. Zhou added that in the face of mounting external uncertainties, Chinese home appliance exporters should diversify business layouts and strengthen supply chain resilience while stepping up investment in research and development and technological innovation to make their products more intelligent, green and energy-saving. Chinese appliance manufacturers are actively adjusting their globalisation strategies to mitigate the risks of over-dependency on too few markets. Haier Smart Home Co Ltd, a subsidiary of China's largest home appliance manufacturer Haier Group, is stepping up efforts to expand its presence in the Middle East through establishing an industrial park that produces air conditioners, TVs, refrigerators and freezers in Egypt. The park is expected to accelerate the company's presence and growth in the Middle East and Africa by leveraging its global supply chain to serve consumers in the region. Li Dongsheng, founder and chairman of Chinese consumer electronics company TCL Technology Group Corp, said, 'We will actively consider increasing industrial centres in Africa and strengthening our business in the Middle East.' Li said Chinese manufacturers should shift from exporting products to exporting industrial capacity, accelerate the building of global industrial chains and improve localised operations in overseas markets. Wu Chun, managing partner of Boston Consulting Group Greater China, said Chinese home appliance makers have accumulated years of advantages in production and supply chains, independent innovation capabilities and world-leading expertise in digital technologies. 'These core advantages can enable them to seize emerging opportunities under the new development landscape,' Wu said, highlighting that Chinese enterprises have gradually shifted their strategic focus in their globalisation processes. — China Daily/ANN
Malaysian Reserve
an hour ago
- Malaysian Reserve
GnRH Antagonists Market on Upward Trajectory During the Forecast Period (2025-2034) Across the 7MM
The GnRH inhibitor market is shifting toward more convenient, patient-focused treatments, driven by oral therapies such as ORGOVYX and YSELTY. As the pipeline continues to grow and indications expand, this drug class is poised for broader clinical use and is likely to play a key role in the future of hormonal suppression in oncology and women's health. LAS VEGAS, Aug. 13, 2025 /PRNewswire/ — DelveInsight's GnRH Receptor Antagonists Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Endometriosis, fibroids, prostate cancer, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging GnRH receptor antagonists, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the GnRH Receptor Antagonists Market Report As per DelveInsight's analysis, the total market size of GnRH receptor antagonists in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as Endometriosis, fibroids, prostate cancer, and others. Leading GnRH receptor antagonist companies, such as Debiopharm, Tiumbio, Antev, and others, are developing novel GnRH Receptor Antagonists that can be available in the GnRH receptor antagonist market in the coming years. Some of the key GnRH receptor antagonists in the pipeline include Debio 4326, Merigolix (TU2670), Teverelix, and others. In May 2025, TiumBio and Daewon Pharmaceutical completed Phase II clinical trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids with positive results. In March 2025, Kissei initiated the Phase III Clinical Trial for the GnRH Antagonist 'Linzagolix' indicated for Endometriosis in Japan. In February 2025, Kissei submitted New Drug Application (NDA) for 'linzagolix' indicated for Uterine Fibroids in Japan. In the EU, linzagolix received marketing authorization for uterine fibroids in June 2022. Discover which indication is expected to grab the major GnRH receptor antagonists market share @ GnRH Receptor Antagonists Market Report GnRH Receptor Antagonists Market Dynamics The GnRH receptor antagonists market is witnessing steady growth driven by advancements in therapeutic applications across a range of hormone-related disorders. These antagonists function by directly inhibiting GnRH receptors in the pituitary gland, thereby suppressing the release of LH and FSH. This mechanism provides a rapid and reversible suppression of sex hormones such as testosterone and estrogen, making them effective alternatives to GnRH agonists, which are associated with an initial hormone surge. Key indications for GnRH receptor antagonists include prostate cancer, endometriosis, uterine fibroids, and assisted reproductive technologies (ART). One of the significant drivers of market expansion is the growing prevalence of hormone-sensitive cancers, particularly prostate cancer in men and endometriosis or uterine fibroids in women. The increasing demand for therapies with improved safety profiles and faster onset of action has created a favorable environment for GnRH antagonists. Moreover, recent product launches such as RELUGOLIX (marketed as ORGOVYX for prostate cancer and MYFEMBREE for uterine fibroids) and ELAGOLIX (marketed as ORILISSA for endometriosis and ORIAHNN for fibroids) have gained regulatory approvals and demonstrated commercial success, further validating the therapeutic potential of this class. Additionally, the market is benefiting from a broader shift towards oral therapies. Unlike older GnRH agonists, many of the newer antagonists are available in oral formulations, improving patient adherence and convenience. This factor is particularly significant in chronic indications where long-term management is necessary. The preference for non-invasive treatment options among patients and providers is reshaping treatment paradigms and expanding the reach of GnRH antagonists beyond hospital settings to outpatient care. However, the market also faces certain challenges. Cost of therapy remains a barrier in several regions, particularly in low- and middle-income countries, where access to advanced hormonal therapies is limited. Furthermore, competition from alternative treatment modalities such as aromatase inhibitors, progestins, and surgical interventions can restrict market penetration in some indications. Intellectual property protection, regulatory requirements, and long development timelines can also impact new entrants and biosimilar competition. In the coming years, continued R&D in expanding the therapeutic use of GnRH antagonists, including potential applications in breast cancer, male infertility, and transgender hormone therapy, is likely to support further market growth. Strategic collaborations, licensing deals, and increasing investments by pharmaceutical companies in reproductive health and oncology are expected to drive innovation and market competitiveness. Overall, the GnRH receptor antagonists market is positioned for sustained growth, underpinned by clinical efficacy, patient-centric delivery formats, and expanding disease awareness. GnRH Receptor Antagonists Treatment Market The introduction of oral GnRH antagonists, known for their rapid onset of action, is reshaping treatment approaches for several prevalent gynecologic and oncologic conditions such as endometriosis, uterine fibroids, and prostate cancer. Over the past decade, the GnRH inhibitor market has undergone a significant transformation, moving from injectable formulations to more convenient oral therapies. Initially, the market was led by FIRMAGON, an injectable GnRH antagonist approved in 2008 for advanced prostate cancer. However, a major turning point came in 2020 with the approval of ORGOVYX by Sumitomo Pharma—the first oral GnRH antagonist for prostate cancer. ORGOVYX marked a clinical advancement by eliminating the testosterone flare linked with GnRH agonists and improving patient convenience by removing the need for injections. Its rapid adoption in androgen deprivation therapy (ADT) highlighted a growing preference for oral options. Another significant development was the approval of YSELTY (linzagolix) in 2022 by the EMA for treating uterine fibroids and endometriosis. Developed by Theramex and Kissei, YSELTY extended the use of GnRH antagonists into women's health, offering a once-daily oral therapy with customizable suppression levels to help mitigate long-term estrogen deficiency effects. This approval further validated the use of oral GnRH inhibitors beyond oncology and underscored their expanding role in broader therapeutic areas. Learn more about the GnRH receptor antagonists @ GnRH Receptor Antagonists Analysis Key Emerging GnRH Receptor Antagonists and Companies Key players in the GnRH receptor antagonist market include Tiumbio (Merigolix), Antev (Teverelix), Debiopharm (Debio 4326), and others. Debio 4326 is an innovative, injectable, and biodegradable formulation of triptorelin, designed to provide extended-release over 12 months for managing central precocious puberty (CPP). Its key advantage lies in significantly reducing injection frequency, thereby easing the treatment experience for children with this rare condition. Developed based on positive efficacy and safety data from existing 1-, 3-, and 6-month triptorelin products, this new version aims to enhance long-term adherence and minimize the emotional and physical stress on both children and their caregivers. Debio 4326 is currently undergoing a Phase 3 clinical trial across North and South America to assess its efficacy and safety. Teverelix is a long-acting, injectable GnRH antagonist formulated using a novel microcrystal technology that addresses the known safety limitations of earlier GnRH antagonist treatments for prostate cancer. With favorable injection site tolerance and a six-week dosing schedule, Teverelix is positioned to offer better patient compliance and improved treatment outcomes. Beyond prostate cancer, it also holds potential for treating benign prostate hyperplasia (BPH), acute urinary retention (AUR), endometriosis, and uterine fibroids. In January 2023, the U.S. FDA reviewed early-stage clinical data (Phase I and IIa) and provided written feedback on the design of Antev's planned Phase III trial for Teverelix, targeting patients with advanced prostate cancer and high cardiovascular risk—an area with significant unmet clinical need. Subsequently, in December 2023, the FDA approved a Phase IIb trial involving 40 patients with advanced prostate cancer. In November 2024, the agency also approved another Phase IIb study for acute urinary retention, set to enroll 390 patients. These regulatory milestones support Antev's broader strategy to advance Teverelix as a targeted therapy for patients with specific medical needs. The anticipated launch of these emerging therapies are poised to transform the GnRH receptor antagonists market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the GnRH receptor antagonists market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about GnRH receptor antagonists clinical trials, visit @ GnRH Receptor Antagonists Treatment GnRH Receptor Antagonists Overview GnRH antagonists mark a notable improvement in androgen deprivation therapy (ADT) for treating hormone-sensitive prostate cancer. These drugs function by directly inhibiting GnRH receptors in the pituitary gland, which quickly suppresses the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a rapid drop in testosterone levels. This direct mechanism avoids the initial testosterone surge, or 'flare', that is often seen with other forms of ADT. A major clinical benefit of GnRH antagonists is their swift action, with testosterone levels typically reaching castration thresholds within days. This rapid hormonal suppression is especially beneficial for patients with metastatic or symptomatic disease who require immediate control. Moreover, GnRH antagonists have shown better cardiovascular safety compared to traditional treatments. For instance, the HERO trial demonstrated that relugolix, a once-daily oral GnRH antagonist, significantly reduced the risk of major cardiovascular events. As a result, these agents are particularly advantageous for patients with existing heart-related conditions. GnRH Receptor Antagonists Epidemiology Segmentation The GnRH receptor antagonists market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases in Selected Indications for GnRH Receptor Antagonist Total Eligible Patient Pool for GnRH Receptor Antagonist in Selected Indications Total Treated Cases in Selected Indications for GnRH Receptor Antagonist GnRH Receptor Antagonists Report Metrics Details Study Period 2020–2034 GnRH Receptor Antagonists Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report Endometriosis, fibroids, prostate cancer, and others Key GnRH Receptor Antagonist Companies Debiopharm, Tiumbio, Antev, Ferring Pharmaceuticals, Sumitomo Pharma, Theramex, Kissei, and others Key GnRH Receptor Antagonists Debio 4326, Merigolix (TU2670), Teverelix, FIRMAGON, ORGOVYX, YSELTY, and others Scope of the GnRH Receptor Antagonists Market Report GnRH Receptor Antagonists Therapeutic Assessment: GnRH Receptor Antagonists' current marketed and emerging therapies GnRH Receptor Antagonists Market Dynamics: Conjoint Analysis of Emerging GnRH Receptor Antagonists Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, GnRH Receptor Antagonists Market Access and Reimbursement Discover more about GnRH receptor antagonists in development @ GnRH Receptor Antagonists Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary of GnRH Receptor Antagonist 4 Key Events 5 Epidemiology and Market Forecast Methodology 6 GnRH Receptor Antagonist Market Overview at a Glance in the 7MM 6.1 Market Share (%) Distribution by Therapies in 2024 6.2 Market Share (%) Distribution by Therapies in 2034 6.3 Market Share (%) Distribution by Indications in 2024 6. Market Share (%) Distribution by Indications in 2034 7 GnRH Receptor Antagonist: Background and Overview 7.1 Introduction 7.2 Treatment 8 Target Patient Pool 8.1 Key Findings 8.2 Assumptions and Rationale: 7MM 8.3 Epidemiology Scenario in the 7MM 8.4 Total Cases in Selected Indications for GnRH Receptor Antagonist in the 7MM 8.5 Total Eligible Patient Pool for GnRH receptor antagonist in Selected Indications in the 7MM 8.6 Total Treated Cases in Selected Indications for GnRH Receptor Antagonist in the 7MM 9 Marketed Therapies 9.1 Key Competitors 9.2 FIRMAGON (degarelix): FERRING PHARMACEUTICALS 9.2.1 Product Description 9.2.2 Regulatory milestones 9.2.3 Other developmental activities 9.2.4 Clinical development 9.2.5 Safety and efficacy 9.3 ORGOVYX (relugolix): Sumitomo Pharma List to be continued in the report 10 Emerging Therapies 10.1 Key Competitors 10.2 Debio 4326: Debiopharm 10.2.1 Product Description 10.2.2 Other developmental activities 10.2.3 Clinical development 10.2.4 Safety and efficacy 10.2.5 Analyst Views 10.3 Teverelix: Antev List to be continued in the report 11 GnRH Receptor Antagonist: Seven Major Market Analysis 11.1 Key Findings 11.2 Market Outlook 11.3 Conjoint Analysis 11.4 Key Market Forecast Assumptions 11.4.1 Cost Assumptions and Rebates 11.4.2 Pricing Trends 11.4.3 Analogue Assessment 11.4.4 Launch Year and Therapy Uptakes 11.5 Total Market Size of GnRH receptor antagonist in the 7MM 11.6 Market Size of GnRH Receptor Antagonist by Indication in the 7MM 11.7 Market Size of GnRH Receptor Antagonist by Therapies in the 7MM 11.8. The United States Market Size 11.8.1 Total Market Size of GnRH Receptor Antagonists in the United States 11.8.2 Market Size of GnRH Receptor Antagonist by Therapies in the United States 11.9 EU4 and the UK Market Size 11.10 Japan Market Size 12 Market Access and Reimbursement 13 SWOT Analysis of GnRH Receptor 14 KOL Views of GnRH Receptor 15 Unmet Needs of GnRH Receptor 16 Bibliography 17 Report Methodology Related Reports Prostate Cancer Market Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key prostate cancer companies, including Sanofi, AstraZeneca, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Janssen Pharmaceutical, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, among others. Prostate Cancer Pipeline Prostate Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key prostate cancer companies, including Curium, Merck, Telix Pharmaceuticals, Exelixis, AstraZeneca, AB Science, Lantheus, Pfizer, Jiangsu Hengrui Pharmaceuticals, Modra Pharmaceuticals, Bristol-Myers Squibb, MacroGenics, Syntrix Pharmaceuticals, Zenith Epigenetics, Xencor, Bristol Myers Squibb, Merus, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Arvinas, Candel Therapeutics, Blue Earth Therapeutics, Ipsen Biopharmaceuticals, LAVA Therapeutics, Essa Pharma, Poseida Therapeutics, Janux Therapeutics, Aurigene Oncology, Sathgen Therapeutics, Full-Life Technologies, NextPoint Therapeutics, AbbVie, SL VAXiGEN, Sorrento Therapeutics, Inc., 858 Therapeutics, Avacta Life Sciences Ltd, Nammi Therapeutics, BeiGene, DualityBio, among others. Endometriosis Market Endometriosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis companies, including Mitsubishi Tanabe Pharma America, Ferring Pharmaceuticals, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Organon, among others. Uterine Fibroids Market Uterine Fibroids Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key uterine fibroids companies, including AbbVie Inc., Addex Therapeutics Ltd, Bayer AG, BioSpecifics Technologies Corp, Dongkook Pharmaceutical Co Ltd, Kissei Pharmaceutical Co Ltd, Myovant Sciences, Ogeda SA, Repros Therapeutics Inc., Takeda Pharmaceutical Company Ltd, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content:
